Vir CEO George Scangos, Set To Retire, Reflects On A Long Career In Biotech

Bayer pharmaceuticals executive Marianne De Backer will succeed Scangos at Vir, tasked with advancing several mid-stage programs in areas like hepatitis B and influenza to late-stage development.

Scangos_George_1200x675
George Scangos is retiring as a biotech CEO

Vir Biotechnology, Inc. CEO and longtime industry veteran George Scangos will retire in April, capping a long career in the biotech industry that included 14 years leading the cancer companyExelixis, Inc., seven years as CEO of Biogen, Inc. and six years overseeing the infectious disease start up Vir. Scangos' leadership track record – from raising cash to executing deals and shepherding drugs to market – earned him the respect of peers and investors.

Scangos will not leave the stage altogether. He will remain as an advisor to Vir through June and assist his...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs

Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By 

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

Executives On The Move: Four New CEOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at Galapagos, plus Bristol Myers Squibb gets a new CMO from AstraZeneca.

More from Scrip

PTC Projects Confidence In Sephience Launch With Royalty Buyback

 
• By 

The company will start shipping its newly launched phenylketonuria drug within two weeks and has bought back global net sales obligations for the treatment.

Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs

Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.

Lilly Confident In Orforglipron Despite Disappointing Phase III Data

 
• By 

Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.